Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...

Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Hypertension can also raise the risk of other health problems, including kidney disease and dementia. The link between blood ...

The robust 77.8% three-month CR rate observed in the UTOPIA trial is highly encouraging and reinforces the potential of UGN-103 to deliver meaningful benefits to patients,” said Liz Barrett, President ...

Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the ...

Reports Q3 revenue $27.482M, consensus $32.47M. “Our launch of ZUSDURI, the first and only FDA-approved medicine for adults with recurrent ...

Here are the 15 hardest video game achievements of all time that players are still struggling to unlock, offering the most ...

Despite majoring in engineering, a Cranberry Township woman took on a health-related project when applying to graduate school ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

The FMI report, “Bladder Liners Market Size, Share, and Forecast 2025–2035,” projects global revenues to increase by USD 1.18 ...

Reports Q3 revenue $32.06M, consensus $35.29M. “We are pleased with the continued strong demand for ANKTIVA in NMIBC CIS. Unit sales grew nearly ...